<DOC>
	<DOCNO>NCT02012634</DOCNO>
	<brief_summary>A Multi-center , III Phase , Randomized Controlled Clinical Study Capecitabine Metronomic Chemotherapy After Standard Adjuvant Chemotherapy Operable Triple Negative Breast Cancer</brief_summary>
	<brief_title>Metronomic Chemotherapy Capecitabine After Standard Adjuvant Chemotherapy Operable Triple Negative Breast Cancer</brief_title>
	<detailed_description>Capecitabine come tablet take mouth . It usually take twice day ( morning evening ) 2 week , follow 1 week break repeat next dosage cycle . In study , capecitabine prescribe dosage 900mg/m2 , maintain whole year standard treatment operable triple negative breast cancer patient . DFS set primary outcome , OS DDFS also observe secondary outcome . Statistical analysis make see whether metronomic therapy capecitabine ( 900mg/m2 ) bring benefit iterms .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Female ; age 18 70 year old ; Histological confirm unilateral invasive carcinoma ( pathological type applicable ) ; Newly diagnose condition allow direct surgery without absolute contraindication surgery ; No mass microscopic tumor residue surgery resection ; Initiate adjuvant chemotherapy within 30 day surgery ; Axillary lymph node positive ( include sentinel lymph node positive lymph node positive axillary dissection ) , example , axillary lymph node negative require primary tumor size must great 1cm ; Definite report ER/PR ( progesterone receptor ) /Her2 receptor show ER/PR/Her2 negative ( specific definition : immunohistochemical detection ER &lt; 10 % tumor cell define ER negative , PR &lt; 10 % positive tumor cell define PRnegative , Her2 0~1+ 2+ determined negative via FISH CISH detect ( amplification ) define Her2 negative ) ; No relevant clinical image evidence metastasis show preoperative examination ( M0 ) ; Without peripheral neuropathy ; ECOG performance score 0 1 ; Postoperative recovery good interval least one week since surgery necessary ; White blood cell count &gt; 4 × 10^9/l , neutrophil count &gt; 2 × 10^9/l , platelet count &gt; 100 × 10^9/l hemoglobin 9g/dl ) ; ASAT ALAT &lt; 1.5 fold upper limit normal value , alkaline phosphatase &lt; 2.5 fold upper limit normal value , total bilirubin &lt; 1.5 fold upper limit normal value ; Serum creatinine &lt; 1.5 fold upper limit normal value ; Women childbearing age take contraception measure treatment ; Cardiac function : echocardiographic examination show LEVF &gt; 50 % ; Informed consent form sign . Bilateral breast cancer carcinoma situ ( DCIS / LCIS ) ; Metastasis location ; Any tumor &gt; T4a ( UICC1987 ) ( accompany skin involvement , lump adhesion fixation , inflammatory breast cancer ) ; Any ER , PR Her2 positive ; Contralateral breast clinically radiologically suspect malignant confirm need biopsy ; Previous neoadjuvant therapy , include chemotherapy , radiotherapy hormone therapy ; Previously suffer malignant tumor ( except basal cell carcinoma cervical carcinoma situ ) , include contralateral breast cancer ; Already enrol clinical trial ; Severe systemic disease and/or uncontrollable infection , unable enrol study LEVF &lt; 50 % ( echocardiography ) ; Suffering severe cardiovascular cerebrovascular disease within six month randomization ( : unstable angina , chronic heart failure , uncontrollable high blood pressure &gt; 150/90mmHg , myocardial infarction brain vascular accident ) ; Known allergic taxane anthracycline agent ; Women childbearing age refuse take contraception measure treatment 8 week completion treatment ; Pregnant breastfeed woman ; Pregnancy test show positive result drug administration enrol study ; With mental illness cognitive impairment , unable understand trial protocol side effect complete trial protocol followup ( systematic evaluation require recruiting study ) ; Without personal freedom independent civil capacity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Triple Negative Breast CancerTNBC（TNBC）</keyword>
</DOC>